MedTrace Logo

Glucocorticoids and Bone in Graves' Ophthalmopathy

NCT03122847 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2025-03-19

Study results available
· View outcomes & findings →

Summary

Continuous use of systemic glucocorticoids decreases bone mineral density and increases fracture risk. Graves' orbitopathy is treated with weekly infusion of high-dose intravenous glucocorticoid. The investigators aim at investigating whether this treatment regimen also affects bone metabolism.

Conditions

  • Graves Ophthalmopathy

Interventions

DRUG

Methylprednisolone

Intravenous methylprednisolone

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • Torben Harsløf

    lead OTHER

Principal Investigators

  • Torben Harsløf, MD, PhD · University of Aarhus

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-07
Primary Completion
2022-07-14
Completion
2024-02-01
FDA Drug
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03122847 on ClinicalTrials.gov